Moderna Surges 177% on Cancer Vaccine Breakthrough
Moderna shares nearly tripled after its personalized mRNA melanoma therapy cut recurrence risk in Phase 3…
Moderna shares nearly tripled after its personalized mRNA melanoma therapy cut recurrence risk in Phase 3…
Pick desks to prioritize. Stored only in this browser.